Slide 1: Q2 Report 2026
AddLife® sl] Ms] Tet] T3]] Q2 Report 2026
Slide 2: Positive development across AddLife's companies
Positive development across AddLife’s companies Margins strengthened: EBITA margin 12.6% (11.9) Labtech 13.4% (12.4) Medtech 12.8% (12.4) Improvement initiatives show clear results Homecare: Significant growth and margins are improving Eye surgery: Positive margin trend continues, demonstrat
Slide 3: Q2 growth supported by organic momentum and acquisitions
Q2 growth supported by organic momentum and acquisitions Revenue growth components EBITA growth components 120 5% 20 7% 100 18 4% 4% 6% 6% 16 80 5% 3% 14 5% 60 3% 105 12 4% 2% 40 10 67 19 1% 8 3% 20 16 1 0% 0% 6 2% 0 4 -20 -30 -1% 1% -1% 2 1 0% -40 -2% 0 0% Currency effect Acquisition Organic growth
Slide 4: P&L Q2 – profit before tax up 29%, driven by revenue growth and gross margin expansion
P&L Q2 – profit before tax up 29%, driven by revenue growth and gross margin expansion • Revenue increased 6% Profit before tax (Q2 2026 vs Q2 2025) • Underlying organic growth +4% 240 • Acquired growth +3% 220 14 56 • Divestment UK endoscopy -1% 200 7 189 1 180 4 • Gross margin improved, driven by
Slide 5: EBITA margin increased to 12.6% in Q2
EBITA margin increased to 12.6% in Q2 EBITA-margin %* 13,0% • Labtech margin Q2: 13.4% (12.4), clear 12,6% 12,5% year-on-year improvement 12,0% 11,9% FY 12.1% • Medtech margin Q2: 12.8% (12.4), 11,4% 11,5% continued year-on-year improvement 11,0% FY 11.3% 10,5% 10,4% • Continued margin expansion rem
Slide 6: Operating cash flow improved and strong cash conversion
Operating cash flow improved and strong cash conversion Operating cash flow per quarter Operating Cash flow and Cash conversion 1000 1600 140% 131% 900 1400 120% 118% 800 111% 1200 101% 700 100% 94% 600 1000 89% 79% 80% 80% 500 76% 800 70% 72% 400 60% 600 300 195 40% 200 165 400 119 82 100 20% 200 0
Slide 7: Strong operating cash flow in Q2; closing cash impacted by acquisition and dividend payments
Strong operating cash flow in Q2; closing cash impacted by acquisition and dividend payments Cash flow 3 month • Operating cash flow SEK 165m (119) 1 400 1 200 390 • Working capital SEK -149m (-180) 1 000 -77 -12 -27 800 771 -78 -32 • The working capital outflow reflected 600 -239 -80 lower account
Slide 8: Net debt up in Q2, primarily due to acquisition and dividend payments
Net debt up in Q2, primarily due to acquisition and dividend payments Change in net debt 5 000 4 800 378 • Net debt increased by SEK 577m 4 710 4 600 -3 in Q2 2026 4 400 145 • Lower cash balance following 4 200 4 133 58 acquisition and dividend payments 4 000 • Majority of loan in EUR – Fx 3 800 inc
Slide 9: Leverage remains comfortably below ambition level
Leverage remains comfortably below ambition level Net debt KPI's 6 000 4 3,8 • Net debt / EBITDA 2.6x, comfortably 3,6 3,6 5 500 3,5 below our ambition of <3.0x 3,2 3,1 3 5 000 2,8 2,9 • The increase from 2.3x in Q1 primarily 2,6 2,3 2,5 reflects acquisition and dividend 4 500 2,2 2 payments during
Slide 10: Labtech Q2 2026
Labtech Q2 2026 • Currency adjusted growth was +7%, with +3% organic and +4% acquired • EBITA margin improved to 13.4% (12.4) • The positive demand trend in the research segment continued and strengthened further • Customers in several Eastern European countries invest in research and diagnostics •
Slide 11: Medtech Q2 2026
Medtech Q2 2026 • Acquired growth +2% and organic growth +5% when adjusted for the divested UK endoscopy business • EBITA margin improved to 12.8% (12.4) • Growth and profitability were strong in the Nordic countries. Advanced products driving growth and margins • Spain: underlying growth was good,
Slide 12: Homecare: Comprehensive product offering
Homecare: Comprehensive product offering HOME ADAPTATION TECHNICAL AIDS Fixed installations: Portable and fixed accessible bathrooms & advanced technical kitchens aids WELFARE TECHNOLOGY CONSTRUCTION Digital solutions incl. safety Accessible solutions for alarms, fall detectors and institutions and
Slide 13: Macro trends support growth in Homecare
Macro trends support growth in Homecare 10-12% MARKET GROWTH Key Market Trends HEALTHCARE AGING POPULATION DIGITALIZATION HEALTHCARE STAFF AGING AT HOME SHORTAGES
Slide 14: AddLife's unique Homecare offering
AddLife´s unique Homecare offering AddLife Homecare business • Comprehensive combined product portfolio • Large share of proprietary products, manufactured in-house • Well established in the leading Nordic market • Growing export business Large Share of Own Products Homecare BU overview Main Export
Slide 15: Summary and outlook Q2 2026
Summary and outlook Q2 2026 • Consistent positive development: Sales, earnings and operating cash flow developed well • Initiatives in advanced products continue to contribute positively to margin improvement and growth Graduation in AddLife Executive • Improvement efforts are yielding clear results
Slide 16: Q&A
Q&A